Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Johnson and Johnson
AstraZeneca
Moodys
Express Scripts

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DAYTRANA

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Daytrana

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00434213 Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA Completed Noven Therapeutics Phase 4 2007-01-01 This is a study designed to characterize the dermal response of DAYTRANA. Subjects will visit the study site over a period of approximately 14 weeks.
NCT00499863 Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD Completed Noven Therapeutics Phase 3 2007-07-01 To assess the efficacy and safety of efficacy of MTS compared to placebo
NCT00501293 Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD Completed Noven Therapeutics Phase 3 2007-08-01 To evaluate the long-term, safety of Methylphenidate Transdermal System (MTS) in aged 13-17 years diagnosed withADHD
NCT00506285 Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD Completed Shire Phase 3 2007-06-01 This study will look at the effectiveness of Methylphenidate Transdermal System (MTS) in treating adult ADHD. MTS has received FDA approval for childhood ADHD but this is the first trial for adult ADHD. Subjects will experience two screening visits and one baseline visit. Those who meet admission criteria will enter the double-blind phase. This will involve two 4-week treatment periods one of which will involve the use of MTS and the other a placebo patch. Subjects who complete the double-blind phase will be allowed to enter a 180-day, open-label MTS phase designed to assess long-term effects.
NCT00506285 Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD Completed University of Utah Phase 3 2007-06-01 This study will look at the effectiveness of Methylphenidate Transdermal System (MTS) in treating adult ADHD. MTS has received FDA approval for childhood ADHD but this is the first trial for adult ADHD. Subjects will experience two screening visits and one baseline visit. Those who meet admission criteria will enter the double-blind phase. This will involve two 4-week treatment periods one of which will involve the use of MTS and the other a placebo patch. Subjects who complete the double-blind phase will be allowed to enter a 180-day, open-label MTS phase designed to assess long-term effects.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Daytrana

Condition Name

Condition Name for Daytrana
Intervention Trials
Attention Deficit Hyperactivity Disorder 7
ADHD 3
Attention Deficit Disorder With Hyperactivity 1
Problem Behavior 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Daytrana
Intervention Trials
Attention Deficit Disorder with Hyperactivity 11
Hyperkinesis 8
Problem Behavior 1
Delayed Emergence from Anesthesia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Daytrana

Trials by Country

Trials by Country for Daytrana
Location Trials
United States 68
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Daytrana
Location Trials
Virginia 4
Ohio 4
New Jersey 3
Florida 3
Kansas 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Daytrana

Clinical Trial Phase

Clinical Trial Phase for Daytrana
Clinical Trial Phase Trials
Phase 4 5
Phase 3 4
Phase 1 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Daytrana
Clinical Trial Phase Trials
Completed 9
Recruiting 2
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Daytrana

Sponsor Name

Sponsor Name for Daytrana
Sponsor Trials
Noven Therapeutics 3
Shire 2
Matthew O'Brien 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Daytrana
Sponsor Trials
Other 11
Industry 5
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Express Scripts
Mallinckrodt
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.